Phospho-CDCP1 (Y707) Antibody

What is CDCP1 and why is Y707 phosphorylation significant?

CDCP1 (CUB domain-containing protein 1) is a transmembrane glycoprotein that plays crucial roles in cell adhesion, migration, and cancer metastasis. The protein contains multiple tyrosine phosphorylation sites in its cytoplasmic domain, including Y707, Y734, Y743, Y762, and Y806. Phosphorylation at Y707 represents one of several important regulatory sites that influence CDCP1's signaling capabilities. While Y734 has been extensively characterized as a primary phosphorylation site by Src family kinases (SFKs), Y707 phosphorylation has been confirmed through multiple mass spectrometric analyses, suggesting its biological relevance . Research indicates that phosphorylation of these residues creates binding sites for SH2 domain-containing proteins, potentially expanding CDCP1's signaling network .

How does Y707 phosphorylation compare to other CDCP1 phosphorylation sites?

The phosphorylation pattern of CDCP1 reveals site-specific functions and regulatory mechanisms:

What are the optimal methods for detecting phosphorylated CDCP1 at Y707?

For reliable detection of phosphorylated CDCP1 at Y707, researchers should consider these methodological approaches:

• Western Blotting: The standard dilution for Phospho-CDCP1 (Y707) antibodies is 1:500-1:2000 . For optimal results:

  • Use freshly prepared cell lysates in appropriate lysis buffers containing phosphatase inhibitors

  • Include positive controls such as peroxovanadate-treated cells, which maximize phosphorylation

  • Run appropriate molecular weight markers (CDCP1 appears at approximately 140 kDa)

  • Block membranes with 5% BSA rather than milk when using phospho-specific antibodies

• Immunoprecipitation followed by Western Blotting: This approach increases sensitivity when detecting low-abundance phosphorylated proteins .

• Mass Spectrometry: For unbiased phosphosite identification and quantification, particularly useful when analyzing the complete phosphorylation profile of CDCP1 .

How should researchers induce and preserve CDCP1 phosphorylation for experimental analysis?

Proper induction and preservation of CDCP1 phosphorylation is critical for experimental consistency:

• Phosphorylation Induction Methods:

  • Treatment with peroxovanadate (PerVO3) for 15 minutes to inhibit phosphatases and maximize phosphorylation

  • Incubation with specific anti-CDCP1 antibodies (5 μg/ml Cub1) to induce CDCP1 clustering and phosphorylation

  • Co-expression with Src family kinases in transfection experiments

• Sample Preservation:

  • Immediate lysis in buffers containing phosphatase inhibitors

  • Maintenance of cold temperatures throughout sample processing

  • Avoidance of repeated freeze-thaw cycles of lysates

• Cell Culture Considerations:

  • Maintain cells in non-confluent state, as contact inhibition may affect CDCP1 phosphorylation

  • Consider the impact of cell adhesion status, as CDCP1 phosphorylation can be modulated by cell detachment

How can researchers distinguish between full-length and cleaved CDCP1 phosphorylation patterns?

CDCP1 exists in both full-length (flCDCP1, ~140 kDa) and cleaved (cCDCP1, ~80 kDa) forms, with potentially distinct phosphorylation patterns and signaling outcomes:

• Experimental Approaches:

  • Use SDS-PAGE conditions that clearly resolve both forms

  • Employ antibodies targeting different epitopes (extracellular vs. intracellular) to confirm identity

  • Create specific expression constructs of flCDCP1 and cCDCP1 as demonstrated by researchers

• Functional Differences:

  • cCDCP1 homodimerizes following cleavage, creating a signaling platform

  • While both forms can be phosphorylated at Y734, cCDCP1 more robustly induces phosphorylation of downstream targets like PKCδ

  • Y707 phosphorylation may occur in both forms, but potential differences in phosphorylation efficiency remain to be fully characterized

What is the relationship between CDCP1 dimerization and Y707 phosphorylation?

Research has established that CDCP1 dimerization represents a critical regulatory mechanism, particularly for the cleaved form. Understanding the relationship between dimerization and Y707 phosphorylation requires consideration of:

How can researchers address contradictory findings regarding Y707 phosphorylation?

The literature reveals some contradictions regarding Y707 phosphorylation detection:

• Antibody Selection Considerations:

  • Different phospho-specific antibodies may have varying sensitivities and specificities

  • Some studies report difficulty detecting Y707 phosphorylation with certain antibodies despite mass spectrometric evidence

  • Try alternative antibodies from different suppliers or detection methods if initial attempts are unsuccessful

• Technical Approaches to Resolve Discrepancies:

  • Implement dual detection methods (e.g., mass spectrometry and immunodetection)

  • Use phospho-tyrosine antibodies of different clones (e.g., 4G10, PY99) as multiple studies showed different results with different antibodies

  • Include appropriate controls: phosphatase-treated samples as negative controls and peroxovanadate-treated samples as positive controls

• Biological Variables Affecting Phosphorylation:

  • Cell type-specific differences in phosphorylation patterns

  • Influence of cell culture conditions (confluency, adhesion status)

  • Differential phosphorylation in cancer versus normal cells

What controls should be included when using Phospho-CDCP1 (Y707) antibodies?

Rigorous experimental design requires appropriate controls:

• Positive Controls:

  • Cells treated with peroxovanadate to maximize phosphorylation

  • Cells expressing constitutively active Src, which enhances CDCP1 phosphorylation

  • Cells stimulated with anti-CDCP1 antibodies known to induce phosphorylation (e.g., Cub1)

• Negative Controls:

  • CDCP1 knockout or knockdown cells to confirm antibody specificity

  • Y707F mutant of CDCP1 to demonstrate phospho-specificity

  • Phosphatase-treated samples to eliminate phosphorylation

  • Non-relevant antibodies of the same isotype for immunoprecipitation controls

• Additional Validation Approaches:

  • Phosphopeptide competition assays to confirm phospho-specificity

  • Correlative analysis with other CDCP1 phosphorylation sites (Y734)

  • Parallel analysis in multiple cell lines with varying CDCP1 expression levels

How does Y707 phosphorylation contribute to CDCP1's role in cancer progression?

CDCP1 has emerged as an important player in cancer progression, with phosphorylation events mediating many of its functions:

• Cancer-Specific Contexts:

  • CDCP1 is upregulated in triple-negative breast cancer (TNBC) and other cancer types

  • Both full-length and cleaved forms are present in cancer specimens, with phosphorylation detected in clinical samples

  • Phosphorylated CDCP1 is associated with metastatic potential

• Signaling Pathways Potentially Influenced by Y707 Phosphorylation:

  • While Y734 phosphorylation has been directly linked to Src binding and downstream PKCδ activation, Y707 phosphorylation may create docking sites for other SH2 domain-containing proteins

  • Potentially contributes to the activation of ERK1/2 and p38 MAPK signaling pathways associated with migration

  • May influence interaction with SHP2 tyrosine phosphatase, recently shown to associate with CDCP1

• Experimental Models to Study Y707 in Cancer Context:

  • Patient-derived cancer samples analyzed for phosphorylation patterns

  • Metastasis models comparing Y707 phosphorylation between primary and metastatic sites

  • Y707F mutants in functional assays of migration, invasion, and anoikis resistance

How do CDCP1 phosphorylation events intersect with other cancer signaling pathways?

CDCP1 functions within a complex network of cancer-associated signaling pathways:

• CDCP1 and Src Family Kinase Signaling:

  • Positive feedback loop between CDCP1 and ERK1/2 signaling downstream of Ras in non-small cell lung carcinoma

  • Src phosphorylates CDCP1, and phosphorylated CDCP1 enhances Src activation, creating a feed-forward loop

• CDCP1 and Growth Factor Receptor Signaling:

  • Cross-talk between CDCP1 and epidermal growth factor receptor (EGFR) pathways

  • Phosphorylated CDCP1 may influence receptor tyrosine kinase signaling cascades

• CDCP1 Phosphorylation and Immune Response:

  • Recent evidence indicates that CDCP1 can signal through CD6 on T cells, inhibiting the JAK-STAT pathway

  • Phosphorylation status of CDCP1 may influence its interaction with immune cells

What emerging technologies could enhance detection and functional analysis of Y707 phosphorylation?

Several cutting-edge approaches may advance our understanding of Y707 phosphorylation:

• Advanced Imaging Techniques:

  • Proximity ligation assays to visualize Y707 phosphorylation in situ

  • Super-resolution microscopy to study phospho-CDCP1 localization and clustering

  • FRET-based biosensors to monitor Y707 phosphorylation dynamics in living cells

• Proteomics and Interactomics:

  • Quantitative phosphoproteomics using stable isotope labeling

  • BioID or APEX proximity labeling to identify proteins interacting with phosphorylated Y707 region

  • Phospho-specific interactome analysis using synthetic phosphopeptides corresponding to Y707

• Structural Biology Approaches:

  • Cryo-EM studies of CDCP1 dimers with differential phosphorylation patterns

  • Structural analysis of phospho-Y707 interactions with potential binding partners

  • Molecular dynamics simulations to understand phosphorylation-induced conformational changes

How might targeting Y707 phosphorylation be exploited therapeutically?

Emerging evidence suggests potential therapeutic applications:

• Antibody-Based Approaches:

  • Antibodies targeting CDCP1 reduce tumor growth and improve safety profiles in preclinical models

  • Phospho-specific antibodies could potentially disrupt specific signaling events

  • Antibody-drug conjugates targeting CDCP1-expressing cancer cells

• Small Molecule Strategies:

  • Inhibitors targeting kinases responsible for Y707 phosphorylation

  • Compounds that disrupt interactions between phospho-Y707 and binding partners

  • Molecules that alter CDCP1 dimerization to modulate phosphorylation patterns

• Combination Therapies:

  • CDCP1-targeted approaches combined with immune checkpoint inhibitors

  • Dual targeting of CDCP1 and Src signaling pathways

  • Sensitization strategies based on CDCP1's role in therapy resistance

What cell models are most appropriate for studying Y707 phosphorylation?

Selection of appropriate cellular models is critical for meaningful phosphorylation studies:

• Cancer Cell Line Considerations:

  • HCT116 colon cancer cells express endogenous CDCP1 that can be phosphorylated

  • Triple-negative breast cancer cell lines show high CDCP1 expression and phosphorylation

  • A549 lung cancer cells lack endogenous CDCP1 and can be used for clean overexpression studies

• Engineered Systems:

  • HEK293T cells lack endogenous CDCP1 and are ideal for transfection-based studies

  • NIH3T3 cells for focus formation assays to study transforming potential

  • CRISPR-engineered cell lines with endogenous CDCP1 mutations at Y707

• Primary Cells and Patient Samples:

  • Patient-derived cancer samples to validate phosphorylation in clinical contexts

  • Primary hematopoietic stem cells given CDCP1's role as a putative stem cell marker

  • Patient-derived xenograft models for in vivo studies of phosphorylation patterns

How can phospho-Y707 signal be distinguished from other phosphorylation events in complex samples?

Differentiation between various phosphorylation events requires sophisticated approaches:

• Phospho-Specific Analytical Techniques:

  • Sequential immunoprecipitation using different phospho-specific antibodies

  • Phospho-flow cytometry with carefully validated antibodies

  • Multiplexed kinase assays to profile multiple phosphorylation events simultaneously

• Phosphatase and Kinase Treatments:

  • Site-specific dephosphorylation using engineered phosphatases

  • In vitro kinase assays with purified proteins to establish phosphorylation hierarchies

  • Pharmacological inhibition of specific kinase pathways to dissect contribution

• Mass Spectrometry Approaches:

  • Multiple reaction monitoring (MRM) to quantify specific phosphopeptides

  • Enrichment strategies using titanium dioxide or immobilized metal affinity chromatography

  • Parallel reaction monitoring for targeted analysis of Y707 phosphopeptides